Milano A, Vouhé P R, Baillot-Vernant F, Donzeau-Gouge P, Trinquet F, Roux P M, Leca F, Neveux J Y
J Thorac Cardiovasc Surg. 1986 Aug;92(2):218-25.
Selection of types of cardiac valve substitutes for children remains controversial. Between 1976 and 1984, 166 children, 15 years of age or younger, underwent aortic (N = 53) or mitral valve replacement (N = 90) or both (N = 23). Biological prostheses were used in 84 patients and mechanical prostheses in 71; both a mitral bioprosthesis and an aortic mechanical valve were used in 11 patients. The overall early mortality was 9%. Mean follow-up intervals were 4.1 years for the bioprosthesis group, 3.3 years for the mechanical valve group, and 3.5 years for the group receiving both. The 7 year survival rates (+/- standard error) were 63% +/- 6% in the bioprosthesis group and 70% +/- 7% in the mechanical valve group (p = NS). After aortic valve replacement the 7 year survival rates were 66% +/- 14% (bioprosthesis group) and 77% +/- 9% (mechanical valve group) (p = NS); after mitral valve replacement the rates were 65% +/- 7% (bioprosthesis group) and 54% +/- 17% (mechanical valve group) (p = NS). The incidence of thromboembolic events was 0.6% +/- 0.4% per patient-year in the bioprosthesis group (none after aortic valve replacement, 0.8% +/- 0.6% per patient-year after mitral valve replacement) and 1.4% +/- 0.8% per patient-year in the mechanical valve group (0.7% +/- 0.7% per patient-year after aortic valve replacement, 4.0% +/- 2.8% per patient-year after mitral valve replacement) (p = NS). The linearized rates of reoperation were 10.4% +/- 1.8% per patient-year (bioprosthesis group) and 2.3% +/- 1.0% per patient-year (mechanical valve group) (p less than 0.001). The 7 year probability rates of freedom from all valve-related complications were 43% +/- 6% in the bioprosthesis group and 86% +/- 4% in the mechanical valve group (p less than 0.001). In the aortic position, a mechanical adult-sized prosthesis can always be implanted, and satisfactory long-term results can be anticipated. In the systemic atrioventricular position, the results are less than satisfactory with either type of prosthesis; every effort should be made to preserve the natural valve of the child.
儿童心脏瓣膜替代物类型的选择仍存在争议。1976年至1984年间,166名15岁及以下儿童接受了主动脉瓣置换术(n = 53)或二尖瓣置换术(n = 90)或两者皆做(n = 23)。84例患者使用了生物瓣膜,71例使用了机械瓣膜;11例患者同时使用了二尖瓣生物瓣膜和主动脉机械瓣膜。总体早期死亡率为9%。生物瓣膜组的平均随访时间为4.1年,机械瓣膜组为3.3年,接受两种瓣膜的组为3.5年。生物瓣膜组7年生存率(±标准误)为63%±6%,机械瓣膜组为70%±7%(p =无显著性差异)。主动脉瓣置换术后,生物瓣膜组7年生存率为66%±14%,机械瓣膜组为77%±9%(p =无显著性差异);二尖瓣置换术后,生物瓣膜组生存率为65%±7%,机械瓣膜组为54%±17%(p =无显著性差异)。生物瓣膜组血栓栓塞事件的发生率为每患者年0.6%±0.4%(主动脉瓣置换术后无事件发生,二尖瓣置换术后每患者年0.8%±0.6%),机械瓣膜组为每患者年1.4%±0.8%(主动脉瓣置换术后每患者年0.7%±0.7%,二尖瓣置换术后每患者年4.0%±2.8%)(p =无显著性差异)。再次手术的线性化率为生物瓣膜组每患者年10.4%±1.8%,机械瓣膜组每患者年2.3%±1.0%(p<0.001)。生物瓣膜组7年无所有瓣膜相关并发症的概率为43%±6%,机械瓣膜组为86%±4%(p<0.001)。在主动脉位置,总是可以植入成人尺寸的机械瓣膜,并可预期获得满意的长期效果。在体循环房室位置,两种类型的瓣膜替代物效果均不太令人满意;应尽一切努力保留儿童的天然瓣膜。